Inappropriate drug prescribing in patients with renal impairment Renal insufficiency Chronic kidney disease Inappropriate prescribing Clinical decision support systems
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with chronic kidney disease stage 3a or higher. 2. Patients who received at least one medication from the list of 35 study medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), Acetazolamide, Acyclovir, Allopurinol, Alogliptin, Amiloride, Apixaban, Atenolol, Bisoprolol, Cefixime, Cephalexin, Ciprofloxacin, Clarithromycin, Co-trimoxazole, Dabigatran, Deferasirox, Digoxin, Enalapril Erythromycin, Fenofibrate, Gabapentin, Gliclazide, Lercanidipine, Levetiracetam, Levofloxacin, Lithium, Norfloxacin, Pregabalin, Probenecid, Rivaroxaban, Rosuvastatin, Silodosin, Sitagliptin, Tenofovir alafenamide (TAF), Tenofovir disoproxil fumarate (TDF) 3. Patients attending the outpatient clinics of Phrapokklao Hospital during the study period.
Exclusion criteria
Exclusion criteria: 1. Patients with acute kidney injury. 2. Patients receiving renal replacement therapy, including hemodialysis or peritoneal dialysis. 3. Patients with incomplete clinical data required for renal function assessment. 4. Patients whose medication orders were issued through refill clinics as repeated dispensing based on previous prescriptions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inappropriate prescribing During the three month period before and after implementation of the automated alert system Review of medication orders for renal dose appropriateness using electronic medical records and predefined renal dosing criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| Acceptance of automated alert recommendations During the three month period before and after implementation of the automated alert system Electronic data extracted from the automated alert system | — |
Countries
Thailand
Contacts
Phrapokklao Hospital